In immunology, we've added novel mechanisms that have the potential ... So, in several large markets, we actually are ahead of Dupixent. And some of that has to do with the way that the label ...

Filippos Maniatis, Healthcare Analyst at GlobalData, remarks, "With Dupixent setting the gold ... enthusiasm about the progress of this mechanism of action. Positive outcomes from clinical trials ...

“Having Dupixent as the gold standard for AD ... GlobalData sharing their excitement about the progress of anti-OX40L mechanism of action. Overall, the positive outcomes from the clinical ...

The use of Dupixent in AD has set a high benchmark ... pharmaceutical companies are investigating agents with different mechanisms of action to provide alternatives to the current standard of ...

This is how biologic treatments can help. Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults, ...

Dupixent continues to be a significant growth ... targets a large market opportunity in thrombosis treatment. While the mechanism isn't fully de-risked and requires large, expensive Phase III ...

Sales of Dupixent grew by an impressive 29% year-over ... targeting anticoagulation with a differentiated mechanism of action. 2. Fianlimab: An antibody targeting LAG-3 for melanoma treatment ...

The success of Dupixent has demonstrated the viability ... With its innovative mechanism of action and established success in asthma, Fasenra could address critical safety and efficacy gaps ...

The drug’s mechanism of action simultaneously inhibits IL-4 and IL-13, which Sanofi says makes it a powerful treatment for type 2 inflammation in multiple diseases. Dupixent has already picked ...

Dupixent becomes the first-ever targeted therapy ... There is also the prospect of another therapy with a new mechanism of action in the next year or two after Amgen and AstraZeneca’s TSLP ...